SCHEMBL1632276

SCHEMBL1632276

NS(=O)(=O)c1ccc(Nc2ncc3cccc(-c4cncc(CNC5CCOCC5)c4)c3n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 3/20 0.42
▸ TBK1 Q9UHD2 3/20 0.42
▸ IKBKE Q14164 1/20 0.42
▸ IKBKB O14920 2/20 0.42
▸ MAPK10 P53779 2/20 0.41
▸ CSF1R P07333 2/20 0.41
▸ TYK2 P29597 2/20 0.41
▸ NUAK1 O60285 1/20 0.41
▸ STK16 O75716 1/20 0.41
▸ CSNK2A2 P19784 1/20 0.41
▸ AAK1 Q2M2I8 1/20 0.41
▸ ULK3 Q6PHR2 1/20 0.41
▸ BMP2K Q9NSY1 1/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ PTK2 Q05397 2/20 0.40
▸ JUN P05412 1/20 0.40
▸ MAPK8 P45983 1/20 0.40
▸ CA1 P00915 3/20 0.40
▸ CA2 P00918 3/20 0.40
▸ CA9 Q16790 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1634289 0.85 CDK1 (0.43) NTRK1TBK1IKBKEIKBKBMAPK10
SCHEMBL1632121 0.83 SYK (0.45) NTRK1TBK1IKBKEIKBKBCSF1R
SCHEMBL1634505 0.83 TBK1 (0.55) NTRK1TBK1IKBKEIKBKBMAPK10
SCHEMBL1633768 0.81 PTK2 (0.45) NTRK1IKBKBMAPK10PTK2CA1
SCHEMBL1632155 0.79 IKBKB (0.46) NTRK1TBK1IKBKEIKBKBMAPK10
SCHEMBL1633715 0.77 NTRK1 (0.42) NTRK1TBK1IKBKEIKBKBMAPK10
SCHEMBL1633524 0.77 JAK2 (0.50) NTRK1TBK1IKBKBCSF1RTYK2
SCHEMBL1633433 0.76 MAPK10 (0.64) NTRK1MAPK10JUNMAPK8CA1
SCHEMBL13498247 0.75 IKBKB (0.44) NTRK1TBK1IKBKEIKBKBCSF1R
SCHEMBL1634316 0.75 TBK1 (0.57) NTRK1TBK1IKBKEMAPK10CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 NTRK1 1997/4885TBK1 539/4885IKBKE 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback